Loading…
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
Legislative Progress
Introduced
September 27, 2018
Latest Action
October 10, 2018
Primary Sponsor
George HoldingRepublican(NC)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
59pct
13d open
vs 7,393 other HR bills in the 115th — cohort avg 50d
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018 This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (9)
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2018 · fourth_quarter · Health Issues
Tariffs on medical devices, medical device tax repeal, servicing of medical device HR 6948, the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018 VA; Focused Ultrasound; medical device tax
Client expense: $475,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, Federal Energy Regulatory Commission (FERC), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Trade Representative (USTR)
2018 · third_quarter · Health Issues
Tariffs on medical devices, medical device tax repeal, servicing of medical devices HR 6948, the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
Client expense: $500,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, Federal Energy Regulatory Commission (FERC), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Trade Representative (USTR)
2018 · fourth_quarter · Health Issues
Tariffs on medical devices, medical device tax repeal, servicing of medical device HR 6948, the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018 VA; Focused Ultrasound; medical device tax
Client expense: $475,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, Federal Energy Regulatory Commission (FERC), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Trade Representative (USTR)
2018 · fourth_quarter · Health Issues
S. 108 - Medical Device Access and Innovation Protection Act H.R. 184 - Protect Medical Innovation Act of 2017 Medical imaging reimbursement H.R. 2118 - Medical Device Servicing Safety and Accountability Act HR 2479 Protecting Business Opportunities for Veterans Act Wireless Medical Telemetry Hospital outpatient reimbursement H.R. 1301 - Continuing Appropriations Amendments Act, 2018 HR 6948 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018 Ultrasound Reimbursement Cyber Security
Client expense: $1,510,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Natl Aeronautics & Space Administration (NASA), Natl Science Foundation (NSF), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
H.R.6948 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018 Cell & Gene Therapy, including reimbursement Personalized Medicine Section 9008 of Patient Protection and Affordable Care Act FSA/HSA - Support reinstating coverage of OTC products 340B Drug Discount Program Dual Eligibles Program DQSA Implementation (Track & Trace) Certified Importer Program Drug Importation Reimbursement for medical devices GMP related to manufacturing sites Biosimilars Low-income Subsidy in Part D REMS Creates Act FCLCA Value of Medicines Drug Cost/Pricing Biosimilars Reimbursement Generic Drugs Medicaid FDA Regulations of Lab Developed Tests (LDT) Reimbursement for LDTs IPAB Generic Drug Labeling Outcomes-based Contracting PREA/BPCA Truthful, Non-Misleading Drug Information Part D Non-interference S.469 - Affordable and Safe Prescription Drug Importation Act Orphan Drugs Drug Pricing Transparency S.456 - RACE for Children Act S.204 - Trickett Wendler Right to Try Act of 2017 and related legislation Drug Compounding CMMI H.R.2641 - Promoting Life-Saving New Therapies for Neonates Act of 2017 Clinical Trials H.R.2430 - FDA Reauthorization Act of 2017 H.R.849 - Protecting Seniors' Access to Medicare Act of 2017 Virtual Clinical Trials S2465 - Sickle Cell Disease Part D Donut Hole PAUSE Act DQSA Implementation Omnibus bill CR PAHPA Reauthorizing Biosimilar Pass Through Payments Value Based Pricing
Client expense: $580,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
2018 · fourth_quarter · Medicare/Medicaid
Issues impacting diagnostic reimbursements. H.R. 6948, Ensure Patient Access to Innovative Imaging Drugs.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Health Issues
Issues related to H.R. 6948, appropriate payment legislation for diagnostic radiopharmaceuticals.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Health Issues
Administrative and legislative monitoring and outreach related to healthcare issues. H.R. 6948, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Medical/Disease Research/Clinical Labs
Administrative and legislative monitoring and outreach related to healthcare issues. H.R. 6948, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Science/Technology
Administrative and legislative monitoring and outreach related to healthcare issues. H.R. 6948, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Insurance
HR 6948 Medicare Diagnostic radiopharmaceutical payment equity act of 2018
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES
2018 · fourth_quarter · Health Issues
Proposals to modify the current reimbursement for radiopharmaceuticals H.R. 6948
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Energy/Nuclear
American Medical Isotopes Production Act of 2012: Section 2: Improving the Reliability of Domestic Medical Isotope Supply - implementation; H.R. 6948, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
Client expense: $970,000 · Firm income: Not reported
Government targets: Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE
H.R.6948 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018 Cell & Gene Therapy, including reimbursement Personalized Medicine Section 9008 of Patient Protection and Affordable Care Act FSA/HSA - Support reinstating coverage of OTC products 340B Drug Discount Program Dual Eligibles Program DQSA Implementation (Track & Trace) Certified Importer Program Drug Importation Reimbursement for medical devices GMP related to manufacturing sites Biosimilars Low-income Subsidy in Part D REMS Creates Act FCLCA Value of Medicines Drug Cost/Pricing Biosimilars Reimbursement Generic Drugs Medicaid FDA Regulations of Lab Developed Tests (LDT) Reimbursement for LDTs IPAB Generic Drug Labeling Outcomes-based Contracting PREA/BPCA Truthful, Non-Misleading Drug Information Part D Non-interference S.469 - Affordable and Safe Prescription Drug Importation Act Orphan Drugs Drug Pricing Transparency S.456 - RACE for Children Act S.204 - Trickett Wendler Right to Try Act of 2017 and related legislation Drug Compounding CMMI H.R.2641 - Promoting Life-Saving New Therapies for Neonates Act of 2017 Clinical Trials H.R.2430 - FDA Reauthorization Act of 2017 H.R.849 - Protecting Seniors' Access to Medicare Act of 2017 Virtual Clinical Trials S2465 - Sickle Cell Disease Part D Donut Hole PAUSE Act DQSA Implementation Omnibus bill CR PAHPA Reauthorizing Biosimilar Pass Through Payments Value Based Pricing
Client expense: $1,330,000 · Firm income: Not reported
2018 · third_quarter · Health Issues
Implementation of Drug Quality and Security Act Proposals to modify the current reimbursement for radiopharmaceuticals H.R. 6948
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Health Issues
Tariffs on medical devices, medical device tax repeal, servicing of medical devices HR 6948, the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
Client expense: $500,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, Federal Energy Regulatory Commission (FERC), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), U.S. Trade Representative (USTR)
2018 · third_quarter · Health Issues
Issues related to H.R. 6948, appropriate payment legislation for diagnostic radiopharmaceuticals.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Health Issues
To advocate for H.R. 6948, appropriate payment legislation for diagnostic radiopharmaceuticals.
Client expense: Not reported · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office